Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors

Background We aimed to describe the most frequently prescribed initial antiretroviral therapy (ART) regimens in recent years in HIV-positive persons in the Cohort of the Spanish HIV/AIDS Research Network (CoRIS) and to investigate factors associated with the choice of each regimen. Methods We analyz...

Descripción completa

Detalles Bibliográficos
Autores: Alejos, Belén|||0000-0001-9571-6471, Suárez-García, Inés|||0000-0002-7016-716X, Bisbal, Otilia|||0000-0003-3746-3378, Iribarren, José Antonio, Asensi, Víctor, Górgolas, Miguel, Muga, Roberto|||0000-0001-6301-431X, Moreno, Santiago|||0000-0002-2843-1094, Jarrín, Inma|||0000-0002-7485-2252
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:274515
Acceso en línea:https://ddd.uab.cat/record/274515
https://dx.doi.org/urn:doi:10.1371/journal.pone.0221598
Access Level:acceso abierto
Palabra clave:SDG 3 - Good Health and Well-being
id ES_ce1cb2479aa175fb38ea133d8d3035ee
oai_identifier_str oai:ddd.uab.cat:274515
network_acronym_str ES
network_name_str España
repository_id_str
spelling Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitorsAlejos, Belén|||0000-0001-9571-6471Suárez-García, Inés|||0000-0002-7016-716XBisbal, Otilia|||0000-0003-3746-3378Iribarren, José AntonioAsensi, VíctorGórgolas, MiguelMuga, Roberto|||0000-0001-6301-431XMoreno, Santiago|||0000-0002-2843-1094Jarrín, Inma|||0000-0002-7485-2252SDG 3 - Good Health and Well-beingBackground We aimed to describe the most frequently prescribed initial antiretroviral therapy (ART) regimens in recent years in HIV-positive persons in the Cohort of the Spanish HIV/AIDS Research Network (CoRIS) and to investigate factors associated with the choice of each regimen. Methods We analyzed initial ART regimens prescribed in adults participating in CoRIS from 2014 to 2017. Only regimens prescribed in >5% of patients were considered. We used multivariable multinomial regression to estimate Relative Risk Ratios (RRRs) for the association between sociodemographic and clinical characteristics and the choice of the initial regimen. Results Among 2874 participants, abacavir(ABC)/lamivudine(3TC)/dolutegavir(DTG) was the most frequently prescribed regimen (32.1%), followed by tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)/elvitegravir(EVG)/cobicistat(COBI) (14.9%), TDF/FTC/rilpivirine (RPV) (14.0%), tenofovir alafenamide (TAF)/FTC/EVG/COBI (13.7%), TDF/FTC+DTG (10.0%), TDF/FTC+darunavir/ritonavir or darunavir/cobicistat (bDRV) (9.8%) and TDF/FTC+raltegravir (RAL) (5.6%). Compared with ABC/3TC/DTG, starting TDF/FTC/RPV was less likely in patients with CD4100.000 copies/mL. TDF/FTC+DTG was more frequent in those with CD4100.000 copies/mL. TDF/FTC+RAL and TDF/FTC+bDRV were also more frequent among patients with CD4 Conclusions The choice of initial ART regimens is consistent with Spanish guidelines' recommendations, but is also clearly influenced by physician's perception based on patient's clinical and sociodemographic variables and by the prescribing hospital location.CoRIS, Cohort 22019-01-0120192019-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/274515https://dx.doi.org/urn:doi:10.1371/journal.pone.0221598reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengInstituto de Salud Carlos III https://doi.org/10.13039/501100004587 RD06/006Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 RD12/0017/0018Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 RD16/0002/0006open accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2745152026-06-06T12:50:31Z
dc.title.none.fl_str_mv Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors
title Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors
spellingShingle Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors
Alejos, Belén|||0000-0001-9571-6471
SDG 3 - Good Health and Well-being
title_short Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors
title_full Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors
title_fullStr Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors
title_full_unstemmed Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors
title_sort Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors
dc.creator.none.fl_str_mv Alejos, Belén|||0000-0001-9571-6471
Suárez-García, Inés|||0000-0002-7016-716X
Bisbal, Otilia|||0000-0003-3746-3378
Iribarren, José Antonio
Asensi, Víctor
Górgolas, Miguel
Muga, Roberto|||0000-0001-6301-431X
Moreno, Santiago|||0000-0002-2843-1094
Jarrín, Inma|||0000-0002-7485-2252
author Alejos, Belén|||0000-0001-9571-6471
author_facet Alejos, Belén|||0000-0001-9571-6471
Suárez-García, Inés|||0000-0002-7016-716X
Bisbal, Otilia|||0000-0003-3746-3378
Iribarren, José Antonio
Asensi, Víctor
Górgolas, Miguel
Muga, Roberto|||0000-0001-6301-431X
Moreno, Santiago|||0000-0002-2843-1094
Jarrín, Inma|||0000-0002-7485-2252
author_role author
author2 Suárez-García, Inés|||0000-0002-7016-716X
Bisbal, Otilia|||0000-0003-3746-3378
Iribarren, José Antonio
Asensi, Víctor
Górgolas, Miguel
Muga, Roberto|||0000-0001-6301-431X
Moreno, Santiago|||0000-0002-2843-1094
Jarrín, Inma|||0000-0002-7485-2252
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv CoRIS, Cohort
dc.subject.none.fl_str_mv SDG 3 - Good Health and Well-being
topic SDG 3 - Good Health and Well-being
description Background We aimed to describe the most frequently prescribed initial antiretroviral therapy (ART) regimens in recent years in HIV-positive persons in the Cohort of the Spanish HIV/AIDS Research Network (CoRIS) and to investigate factors associated with the choice of each regimen. Methods We analyzed initial ART regimens prescribed in adults participating in CoRIS from 2014 to 2017. Only regimens prescribed in >5% of patients were considered. We used multivariable multinomial regression to estimate Relative Risk Ratios (RRRs) for the association between sociodemographic and clinical characteristics and the choice of the initial regimen. Results Among 2874 participants, abacavir(ABC)/lamivudine(3TC)/dolutegavir(DTG) was the most frequently prescribed regimen (32.1%), followed by tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)/elvitegravir(EVG)/cobicistat(COBI) (14.9%), TDF/FTC/rilpivirine (RPV) (14.0%), tenofovir alafenamide (TAF)/FTC/EVG/COBI (13.7%), TDF/FTC+DTG (10.0%), TDF/FTC+darunavir/ritonavir or darunavir/cobicistat (bDRV) (9.8%) and TDF/FTC+raltegravir (RAL) (5.6%). Compared with ABC/3TC/DTG, starting TDF/FTC/RPV was less likely in patients with CD4100.000 copies/mL. TDF/FTC+DTG was more frequent in those with CD4100.000 copies/mL. TDF/FTC+RAL and TDF/FTC+bDRV were also more frequent among patients with CD4 Conclusions The choice of initial ART regimens is consistent with Spanish guidelines' recommendations, but is also clearly influenced by physician's perception based on patient's clinical and sociodemographic variables and by the prescribing hospital location.
publishDate 2019
dc.date.none.fl_str_mv 2
2019-01-01
2019
2019-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/274515
https://dx.doi.org/urn:doi:10.1371/journal.pone.0221598
url https://ddd.uab.cat/record/274515
https://dx.doi.org/urn:doi:10.1371/journal.pone.0221598
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.relation.none.fl_str_mv Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 RD06/006
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 RD12/0017/0018
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 RD16/0002/0006
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419939385835520
score 15,300719

Similares en LA Referencia